Peter C. Farrell
Peter C. Farrell's purchase track record
Peter C. Farrell has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/6/2022 | EOLS | $91K | -20.2% | +1.9% | +2.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Arcturus Shares Rise on Phase II Data and Analyst Upgrades. Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Evolus (EOLS) Passes Momentum Screens. Evolus Inc. has recently met the criteria for the Minervini Trend Template and a high growth momentum screen. This suggests the stock is showing signs of upward price strength and volume activity. While the company trades well below its average analyst target price, these technical signals indicate a shift in trading patterns.
Transaction History
| RMD | ▼ Sell | Open Market | 970 | $228K | 9/2/2026 | View on chart |
| RMD | ▼ Sell | Open Market | 8,000 | $1.8M | 8/5/2026 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $450K | 4/1/2026 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $520K | 3/4/2026 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $503K | 2/4/2026 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $498K | 1/7/2026 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $503K | 12/3/2025 | View on chart |
| RMD | ▲ Buy | Grant | 536 | $0 | 11/20/2025 | View on chart |
| RMD | ▲ Buy | Option Exercise | 11,442 | $1.2M | 11/14/2025 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 7,314 | $1.8M | 11/14/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $504K | 11/12/2025 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 163 | $41K | 11/11/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 945 | $241K | 7/2/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $495K | 6/4/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $485K | 5/7/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $439K | 4/2/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $455K | 3/5/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $484K | 2/5/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $462K | 1/2/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $491K | 12/4/2024 | View on chart |
| RMD | ▲ Buy | Grant | 542 | $0 | 11/20/2024 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 528 | $133K | 11/11/2024 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $497K | 11/6/2024 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $474K | 10/2/2024 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $480K | 9/4/2024 | View on chart |
| ARCT | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 | View on chart |
| RMD | ▼ Sell | Gift | 68,200 | $0 | 5/15/2024 | View on chart |
| RMD | ▼ Sell | Open Market | 10,935 | $2.0M | 2/22/2024 | View on chart |
| RMD | ▲ Buy | Grant | 1,768 | $0 | 11/16/2023 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 325 | $47K | 11/13/2023 | View on chart |
| RMD | ▼ Sell | Open Market | 12,600 | $3.0M | 5/3/2023 | View on chart |
| EOLS | ▲ Buy | Grant | 8,293 | $0 | 1/27/2023 | View on chart |
| RMD | ▲ Buy | Grant | 1,122 | $0 | 11/16/2022 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 128 | $29K | 11/11/2022 | View on chart |
| RMD | ▼ Sell | Open Market | 9,050 | $2.0M | 10/31/2022 | View on chart |
| RMD | ▼ Sell | Gift | 4,550 | $0 | 10/31/2022 | View on chart |
| EOLS | ▲ Buy | Open Market | 10,000 | $91K | 9/6/2022 | View on chart |
| EOLS | ▲ Buy | Grant | 15,568 | $0 | 1/24/2022 | View on chart |
| RMD | ▲ Buy | Grant | 478 | $0 | 11/18/2021 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 342 | $89K | 11/11/2021 | View on chart |
| RMD | ▼ Sell | Gift | 36,670 | $0 | 8/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released
ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.